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Abstract: Food allergy affects a small but important number of children and adults. Much of the
morbidity associated with food allergy is driven by the fear of a severe reaction and fatalities continue to
occur. Foods are the commonest cause of anaphylaxis. One of the aims of the European Union-funded
Integrated Approaches to Food Allergen and Allergy Risk Management (iFAAM) project was to improve
the identification and management of children and adults at risk of experiencing a severe reaction. A
number of interconnected studies within the project have focused on quantifying the severity of allergic
reactions; the impact of food matrix, immunological factors on severity of reactions; the impact of co-
factors such as medications on the severity of reactions; utilizing single-dose challenges to understand
threshold and severity of reactions; and community studies to understand the experience of patients
suffering real-life allergic reactions to food. Associated studies have examined population thresholds and
co-factors such as exercise and stress. This paper summarizes two workshops focused on the severity of
allergic reactions to food. It outlines the related studies being undertaken in the project indicating how
they are likely to impact on our ability to identify individuals at risk of severe reactions and improve
their management.
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Abstract
Food allergy affects a small but important number of children and adults. Much of the morbidity 
associated with food allergy is driven by the fear of a severe reaction, and fatalities continue to 
occur. Foods are the commonest cause of anaphylaxis. One of the aims of the European Union 
funded Integrated Approaches to Food Allergen and Allergy Risk Management (iFAAM) project 
was to improve the identification and management of children and adults at risk of experiencing a 
severe reaction. A number of interconnected studies within the project have focused on 
quantifying the severity of allergic reactions; the impact of food matrix, immunological factors on 
severity of reactions; the impact of co-factors such as medications on the severity of reactions; 
utilising single dose challenges to understand threshold and severity of reactions; and community 
studies to understand the experience of patients suffering real-life allergic reactions to food. 
Associated studies have examined population thresholds, and co-factors such as exercise and 
stress. This paper summarises two workshops focused on the severity of allergic reactions to 
food. It outlines the related studies being undertaken in the project indicating how they are likely 
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1 Background 
2 Food allergy affects around 5% of preschool children and 2% of school children and adults (1). 
3 The prevalence has increased in recent decades with a doubling in peanut allergy (2) and similar 
4 increases in hospitalisations due to anaphylaxis in Europe, USA and Australia (3). Food allergy is 
5 the commonest cause of anaphylaxis (4), a systemic and potentially life-threatening allergic 
6 reaction (5). Anxiety surrounding the fear of a severe allergic reaction has a major impact on 
7 food-allergic patients and their families. For example, impaired quality of life is seen with the 
8 necessary avoidance strategies, need to carry rescue medication and the associated fear of an 
9 allergic reaction (6). Food-induced allergic reactions result in many presentations to hospital each 
10 year and there are, often well publicised, cases of fatal anaphylaxis (7). Unfortunately these 
11 severe allergic reactions are not predictable (8), and individuals with the same food allergy can 
12 have very different reactions following ingestion due to co-factors (3,9). Such co-factors include, 
13 among others, exercise, viral infections and several medications, whose presence around the 
14 time of reaction may be associated with the development of more severe symptoms. The risks 
15 associated with having food allergy are primarily described by the risk of having a severe allergic 
16 reaction. The management of patients with food allergy is also driven by risk. With increasing risk, 
17 more rigorous avoidance strategies are recommended and adrenaline auto-injectors are 
18 prescribed to manage any future severe allergic reactions (5).  
19
20 Integrated Approaches to Food Allergen and Allergy Risk Management (iFAAM) is a European 
21 Union funded FP7 project. iFAAM aims to reduce the burden of food allergy through a number of 
22 integrated activities. The project has developed evidence-based approaches and tools to improve 
23 both the management of allergens in food as well as the management of food allergy. Many of 
24 these activities are focused on the severity of allergic reactions. This paper is a summary from 
25 two workshops.  Firstly an iFAAM workshop held in Rome, Italy on Saturday 15th October 2016. 
26 The aims of the workshop were to consider how best to (i) identify patients at risk of severe 
27 reactions and situations that may impact on severity of reaction, and (ii) manage patients at risk 
28 of severe reactions, particularly around high risk situations. Secondly a ILSI Europe Food Allergy 
29 Symposium held in Madrid, Spain between 18th and 20th April 2018 where the final iFAAM project 
30 findings were reviewed and discussed. The paper describes the iFAAM severity activities and 
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34 Quantifying the severity of allergic reactions 
35 Allergic reactions to food vary in severity, ranging from isolated oral symptoms, to relatively mild 
36 cutaneous and gastrointestinal symptoms and to potentially life-threatening respiratory and 
37 cardiovascular features (5). Healthcare professionals use the severity of a reaction to guide 
38 treatment for that event and to inform future management of the patients. Being able to accurately 
39 assess and describe the symptoms and signs of severe allergic reactions is therefore vital. A 
40 number of systems have been developed to quantify the severity of allergic reactions to different 
41 agents and in various circumstances, for example: venom (10,11), food (11-18), drugs (19,20) 
42 and adverse reactions to allergen immunotherapy (21,22). None are in widespread use, perhaps 
43 because none is ideal. They were all developed using expert opinion, and none has been 
44 validated. Major limitations of the current schemes include a lack of discrimination between non-
45 anaphylactic reactions of varying severity, lack of applicability to multiple allergen types, and  they 
46 are  not readily translatable into clinical management. For more details, see the recent European 
47 Academy of Allergy and Clinical Immunology position paper (23). 
48
49 To start to address these gaps, iFAAM has developed a Food Allergy Severity Score (FASS) with 
50 two linked formats, a numerical nFASS developed with mathematical modelling and an ordinal 
51 oFASS developed by experts’ consensus with 5 grades that can be reduced to 3 (mild-moderate-
52 severe) to facilitate rapid assessment and ease of communication within most clinical settings. 
53 The two scores have undergone internal validation using the EuroPrevall outpatient clinic 
54 database (24), and external validation using different data sets that cover different foods, 
55 paediatric and adult patients, and the whole spectrum of severity in food allergy. A manuscript 
56 covering the development and validation will be submitted for publication in 2019. Further work is 
57 planned to validate the system with other allergic triggers. 
58
59 The availability of an appropriately developed and validated severity scoring tool will have an 
60 important impact on patient care. A harmonised approach to defining severity in different 
61 populations will allow data from different studies to be directly compared. Given the relationship 
62 between past and future severity of reactions, this would allow the development of better 
63 prediction models to identify patients at risk of future anaphylaxis. Clinically, the oFASS scale 
64 should improve communication of reaction severity between primary care, acute providers and 
65 allergy specialists as well as patients. This should enable specialists to better define individuals 
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67 measure in research trials; to compare severity between populations and triggers; and to analyse 
68 the impact of other factors (as discussed below) and interventions in food allergy severity.
69
70 Impact of food matrix on severity (and threshold) of allergic reactions 
71 The food matrix can affect the uptake of nutrients in the same way that the formulation of different 
72 drugs may affect their absorption (25,26). This phenomenon results from the physicochemical 
73 nature of the food matrix – either the natural structure of plant and animal foods (formed of 
74 organelles, cells and tissues), or the fabricated foods (such as gels, dispersions, foams and 
75 emulsions). Allergens can also become entrained in the structures formed by these other food 
76 components. The food matrix affects the amount of a nutrient in the gut lumen which is available, 
77 after digestion, to be absorbed by the body, a property generally known as bio-accessibility 
78 (25,26). Coming from the field of molecular nutrition, this concept is relevant to understanding 
79 how food allergens are released from food and interact with effector cells in the body to elicit an 
80 allergic reaction. 
81
82 The first description of a matrix effect on clinical reactivity to foods was a repeat food challenge 
83 study in four patients where the fat content of a chocolate-based challenge vehicle was increased 
84 to 31.5% from 22.9 % (w/w) by the addition of a white, high melting point bakery fat (27). Three 
85 patients did not experience the mild oral symptoms that generally precede a reaction and 
86 consequently consumed at least a 10-fold higher dose of peanut in the higher fat challenge. 
87 These observations led to the hypothesis that the allergen was less bio-accessible in the oral 
88 cavity when presented in the higher fat matrix. However, it is likely that the melting point of the 
89 chocolate challenge was increased from 29-32°C by the use of a high melting point (47-48°C) fat, 
90 as well as altering the fat crystal structure of the chocolate. A comparison of a water continuous 
91 chocolate dessert matrix and dark chocolate bars in seven patients with either peanut or hazelnut 
92 allergy showed the chocolate bar (35% (w/w) fat) resulted in a higher cumulative threshold dose 
93 or reaction than the dessert matrix (8% (w/w) fat) (28). Magnetic resonance imaging (MRI) 
94 showed the gastric residence time for the chocolate bar was much longer than the dessert which 
95 might explain the delay in development of symptoms during the challenge with the chocolate bar 
96 (28).  There is also evidence that presentation of allergens in a baked matrix requires a higher 
97 dose to be administered to elicit a reaction. For example, cow’s milk allergic patients have been 
98 found to reacted at lower doses to milk in a screening challenge than they did in the up-dosing for 
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100 show a similar matrix effect with egg and cow’s milk (30,31). An impact on the threshold dose and 
101 severity of reactions was also observed in a group of hazelnut allergic patients when capsules 
102 were used to deliver challenge doses, rather than a complex pudding matrix (32). In this study the 
103 average threshold dose was increased by 3-fold, the lowest observed adverse effect level being 
104 increased by 10-fold and eight subjects experiencing no reaction even after consumption of 10g 
105 of hazelnut. 
106
107 Insights are being gained into the mechanisms whereby the food matrix might affect allergen bio-
108 accessibility through in vitro digestion studies, using either batch or dynamic models of digestion. 
109 An issue remains regarding the validation of such models using human studies, either by 
110 analysing the intestinal contents from ileostomy patients or from intubation studies, although the 
111 latter are limited to the study of liquid meals because of the constraints of nasogastric sampling. 
112 However, studies are lacking directly linking in vivo studies on clinical reactivity to foods, and in 
113 vitro studies investigating bio-accessibility of allergens during mastication and gastro-intestinal 
114 digestion, and subsequent uptake into the circulation.  It is inevitable that the number of studies 
115 where repeat challenges have been undertaken in the same study population are small, and 
116 drawing conclusions about matrix effects in populations is difficult and may be misleading, 
117 especially if differences in severity of reaction, but not threshold dose are to be defined. 
118
119 Addressing these gaps is a major objective of the iFAAM project with focus being placed on 
120 peanut. The differences between baked matrices (cookies) and a water continuous dessert matrix 
121 have been investigated in the iFAAM project. Further studies will be required using the same 
122 systematic approach to identify the common rules governing bio-accessibility of food allergens in 
123 complex food matrices. Such studies will inform food allergen management plans and support 
124 evidence-based risk assessment of novel foods. Such knowledge is crucial to assessing the 
125 allergenic risks posed by new technologies, such as 3D printing of foods, and novel functional 
126 ingredients being developed to improve nutritional quality of foods and address the grand 
127 challenge of food security.  
128
129 The influence of intrinsic immunological factors on reaction severity
130 Given the pathophysiology of IgE-mediated reactions, it seems likely that the nature of food 
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132 reaction to happen at all. For example, the qualitative nature of the IgE-response determines 
133 whether a food allergic person may react to “stable” allergens (i.e. highly abundant digestion-  or 
134 processing-resistant allergens) such as the storage proteins of peanuts, tree nuts and seeds or to 
135 “unstable” allergens such as the PR-10 related allergens cross-reacting with the birch pollen 
136 allergen Bet v 1, such as hazelnut Cor a 1.04, apple Mal d 1, or even peanut Ara h 8 (33). The 
137 avidity and affinity of the specific IgE-allergen interaction has been associated with the likelihood 
138 of an allergic response (34). Together with prior reaction history, this may help to predict the 
139 likelihood of a future severe reaction in appropriate individuals. Looking at the specific IgE in a 
140 more quantitative manner, such as relating a specific IgE-titre to severity, has generated 
141 equivocal results (3). 
142
143 Immunoglobulins of the IgG-isotype are not considered to play a pathogenic role in food 
144 hypersensitivity and their measurement is discouraged as a diagnostic marker for food allergy 
145 (5,35). It has however been speculated that non-IgE isotypes - also including IgA - may offer 
146 protection from food-induced IgE-mediated reactions, in a manner similar to that believed to occur 
147 during allergen-specific immunotherapy. For example, food-specific IgG4 was reported to block in 
148 vitro reactions in basophils and mast cells to peanut (36). Little is known though as to whether 
149 such antibodies provide real-life protection and can reduce severity of food-induced allergic 
150 reactions. While this has been observed in studies of tolerance induction, there are few data to 
151 indicate whether IgG isotypes are useful either for predicting outcome or severity of allergic 
152 reactions at oral food challenge under medical supervision. In the iFAAM project, the prognostic 
153 value of specific IgG4 was studied in a cohort of 137 patients with challenge proven peanut 
154 allergy and 25 sensitized tolerant subjects. Although IgG and IgG4 over IgE ratios were indeed 
155 found to be inversely associated with severity of reactions during challenge, they did not predict 
156 challenge outcomes better than IgE alone (37).
157
158 Following the cross-linking of two or more receptor-bound IgE-molecules by allergens, effector 
159 cells - primarily believed to be mast cells - become activated. Basophils may also contribute to 
160 reaction severity, with evidence of both basophil activation and basophil trafficking in allergic 
161 reactions due venom and food (38). The relationship between basophil activation/trafficking and 
162 reaction severity needs to be further explored. Studies of the cellular compartment of IgE-induced 
163 reactions, in particular mast cells, have been hampered by the question as to which anatomical 
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165 tract, is it absorbed systemically and distributed to target organs such as the vascular system, the 
166 lungs and the upper airways to induce local mast cell activation? Or does it activate mast cells 
167 lining the digestive tract, resulting in the release of inflammatory mediators from the gut which are 
168 then distributed systemically? Alternatively, allergen absorption may occur across the buccal 
169 mucosa (39), resulting in rapid systemic allergen distribution independent of absorption distal to 
170 the mouth: such rapid absorption may explain the observation that anaphylaxis can occur within 
171 minutes of ingestion.
172
173 Human mast cells originate from hematopoietic stem cells residing in the bone marrow and bear 
174 the surface markers CD34, CD117 and CD13. Mast cell progenitors leave the bone marrow and 
175 travel by the circulation to the peripheral sites where they home to vascular endothelium and 
176 enter peripheral tissues upon recruitment. In the tissue immature lineage mast cells fully develop 
177 into mature granule-containing mast cells. The differentiation and maturation of mast cells is 
178 directed by cytokines in the local microenvironment. Stem cell factor (SCF) is essential for mast 
179 cell differentiation. SCF binds to CD117 (c-kit) and control development and survival of mast 
180 cells. Recently published studies have used in vitro derived mast cells to delineate a possible 
181 correlation between mast cells response to allergen and asthma or atopic status, (40,41). Similar 
182 studies would be needed to elucidate whether mast cells from food allergic patients are 
183 predisposed to a higher activation level thus determining the severity of reactions in food allergy.
184
185 The impact of medications as co-factors in allergic reactions 
186 The severity of allergic reactions to foods varies significantly – even within the same individual – 
187 and while differences in the exposure dose may contribute to this observation, severity is clearly 
188 impacted upon by a range of other influences (“co-factors”), independent of dose. One co-factor 
189 thought to be responsible for increasing the severity of reactions is medications. A knowledge of 
190 the impact of specific medications on the severity of allergic reactions may allow us to provide 
191 information to affected individuals to help them avoid risky situations. 
192
193 Proton-pump inhibitors 
194 Gastric enzymes, such as pepsins, require an acidic environment to function. Following treatment 
195 with proton-pump inhibitors (PPI), which reduces gastric acidity to pH 4.0 or higher, pepsin 
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197 allergenic potential from being fully degraded (43), resulting in sensitisation and the development 
198 of clinical allergy. In one study, 5 of 153 patients treated with anti-ulcer medication for three 
199 months developed specific IgE to hazelnut and clinical symptoms; three of them developed 
200 symptoms under single-blind, placebo-controlled food challenges, with either pruritus or urticaria, 
201 and the remaining two upon accidental ingestion, with OAS or urticaria (44). In another report, 
202 patients with fish allergy underwent blinded food challenges with fish extract digested with gastric 
203 enzymes at pH 2.0 and 3.0. Fish extract digested at pH 3.0 triggered reactions at 10- to 30-fold 
204 lower cumulative challenge doses than extract treated at pH 2.0, and two of four patients reacted 
205 only to the latter. These data suggest that impaired digestion might put the patients with food 
206 allergy at a higher risk of developing symptoms at lower doses and at potential risk of more 
207 severe allergic reactions (45). This effect, however, has not yet been demonstrated in a well-
208 controlled, double-blind, placebo-controlled food challenge (DBPCFC) setting, or in a larger study 
209 cohort.
210
211 Given this, within the iFAAM project the impact of PPI on severity of food-induced allergy 
212 symptoms and minimum eliciting dose has been studied at two geographically different centres, 
213 Zurich and Madrid in a randomised double-blind placebo-controlled clinical trial (EUDRA CT nr 
214 2015-001863-38), analysing food reactivity by DBPCFC. Patients with walnut allergy have 
215 undergone three food challenges (two active, one placebo session) with a pre-treatment with 
216 either PPI or placebo. Publication of results is expected in 2019.
217
218 Non-steroidal, anti-inflammatory drugs (NSAIDs)
219 NSAID-enhanced, food-induced, allergic reactions are mainly reported in patients with food-
220 dependent, exercise-induced anaphylaxis (FDEIA) (46) or in Lipid Transfer Protein (LTP)-
221 sensitized individuals from Mediterranean countries. A number of case reports or series have 
222 been published (9,47). In a French case-control study, the odds ratios for severe food-induced 
223 anaphylaxis  associated with aspirin and other NSAIDs were 10.8 and 8.2 respectively (48). A 
224 third (11/34) of food-induced anaphylaxis in LTP syndrome patients were cofactor-dependent 
225 (mainly NSAID) by history in one recent study (aspirin, ibuprofen, diclofenac, metamizol) (49). In 
226 another retrospective study, 58% (43/74) of patients with co-factor-induced mainly LTP-mediated 











This article is protected by copyright. All rights reserved
229 In just a few cases, the effect of NSAIDs on the manifestation of food allergy has been assessed 
230 in vivo. Matsukura (46) observed an anaphylactic reaction in two patients under combined aspirin 
231 and wheat challenge and Matsuo (51) observed allergic reactions in three other patients in a 
232 similar setting. Brockow et al. has investigated aspirin as a cofactor for WDEIA, performing gluten 
233 challenges under exercise with aspirin intake but unfortunately aspirin was combined with alcohol 
234 as a second and therefore confounding cofactor (52). One hypothesis for the NSAID-related 
235 enhancement of food allergy is the induction of increased gastrointestinal barrier permeability by 
236 affecting the function of gastric epithelial tight junctions, which may increase the absorption of 
237 allergens (53). Elevated gliadin concentration in serum has been observed with NSAID intake in a 
238 dose-dependent manner, even in low-dose-aspirin treatment (46,51,52,55). Another hypothesis 
239 postulated is a direct NSAID effect on mast cell function (9,56) and basophils (57).
240
241 Angiotensin-converting enzyme (ACE) inhibitors and beta-blocking agents
242 Both drugs have been reported to aggravate allergic reactions (refs) although other studies would 
243 disagree (58-62). In a French case-control study, the odds ratios for severe anaphylaxis with co-
244 existing beta-blocker and ACE inhibitors treatment were 6.8 and 13.0 respectively (48). Risk 
245 factor analysis in 4783 patients from the anaphylaxis registry of the German-speaking countries 
246 calculated a modest but significant increase of odds ratio (OR increase) for the combined use of 
247 these drugs (63,64). Comparing patients (adjusted for age and sex) with severity grade I/II versus 
248 grade III/IV, there was no significant effect for isolated ACE inhibitor or beta-blocker intake. There 
249 was only a significant effect observed for the isolated beta-blocker intake if grades I to III versus 
250 grade IV were analysed (64). These data were supported by a mouse model (63). Nevertheless, 
251 more studies are needed to assess the impact of ACE inhibitors and beta-blockers on the severity 
252 of allergic reactions.
253
254 The impact of exercise and physiological stress on severity of allergic reactions 
255 Other potential co-factors are exercise and physiological stress (eg sleep deprivation). They may 
256 also be responsible for some of the large variation in severity of allergic reactions in individual 
257 patients. One approach to look at this is to focus on threshold doses, the smallest amount of 
258 allergen required to induce an allergic reaction in individuals. Population dose-distribution curves 
259 describe the proportion of a population with a specific food allergy who will react to increasing 
260 doses of the allergen (Figure 1). Co-factors may be able to shift population dose-distribution 
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262 increasing the severity of the reaction. Conversely, as described previously, other co-factors may 
263 have the opposite effect (e.g. remind readers of one) and shift the dose-distribution curves 
264 towards a less sensitive population (Figure 1). Understanding these population-based dose-
265 distribution curves, the factors which might impact upon them, and the magnitude of this effect is 
266 crucial to guide the advice about when precautionary allergen labelling (PAL) should be applied to 
267 food products. With better informed models, higher reference doses for governmental and 
268 industry-based food allergen management programs may be acceptably safe (65).
269
270 These questions have led to the development of the Threshold Reactivity Clinical Evaluation 
271 (TRACE) Study, associated with the iFAAM consortium and funded by the United Kingdom Food 
272 Standards Agency. One hundred peanut-allergic adults are being challenged with peanut: an 
273 initial baseline peanut challenge to establish their threshold, and then three further challenges in 
274 a random order, including one after sleep deprivation, another with concurrent exercise and a 
275 repeat baseline challenge. A comparison of challenges with and without sleep deprivation and 
276 exercise will allow within-patient variability on threshold to be determined, as well as any 
277 additional impact of sleep deprivation and exercise on the threshold for reactivity. Additionally, the 
278 study offers the opportunity to also look at the impact of these co-factors on reaction severity and 
279 will provide dose-distribution modelling for a UK adult population.
280
281 These data will be important in informing better allergen management in the food industry as they 
282 should provide a more robust evidence base for harmonised reference doses and therefore 
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289 Figure 1. How do extrinsic factors affect threshold and severity of allergic reactions? 
290
291 Extrinsic factors may influence both the threshold and severity of allergic reactions. They may 
292 reduce the threshold dose that induces an allergic reaction in a percentage of the allergic 
293 population (bottom line) while reducing (left) or increasing (right) the severity of reactions. Other 
294 extrinsic factors may have the opposite effect increasing the threshold dose that induces an 
295 allergic reaction in a percentage of the allergic population (top line) and either reducing (left) or 
296 increasing (right) the severity of reactions. See also Hourihane and Knulst (66). 
297
298
299 What can we learn from single dose challenges?
300 Population dose-distribution modelling of individual threshold doses can be used to establish 
301 public health measures such as the control of PAL.  These dose-distribution curves can be used 
302 to define reference doses. For example, the dose eliciting a reaction in 1% of individuals with 
303 peanut allergy (eliciting dose, ED01) has been estimated to be 0.2 mg peanut protein, using log-
304 normal and log-logistic models (67,68).  The ED01 was selected by the VITAL Scientific Expert 
305 Panel (VSEP) because it is predicted to protect 99% of the peanut-allergic population against any 
306 reaction. This dose can be used to inform allergen action levels as decision points to apply PAL. 
307 Alternatively a different protection goal could be chosen by using the ED05, the dose at which 95% 
308 of the population are protected (69); this has the advantage of giving higher action levels 
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310 allergic reactions to unintentionally present allergen(s). Whatever the reference dose used, it is 
311 clearly critical to confirm the benign nature of reactions at that dose, and particularly to ensure 
312 that their nature and frequency remain tolerable in public health terms.
313
314 It is important that eliciting doses derived from dose-distribution models are validated. The 
315 recently completed Peanut Allergen Threshold Study (PATS) has focused on the ED05 for peanut 
316 in a single dose (66,69). Only 8/375 (2.1%) subjects had convincing objective reactions according 
317 to pre-defined criteria, all mild. In iFAAM, the same protocol has been applied to milk, egg and 
318 hazelnut to validate the ED05 for each of these important allergens, albeit across much wider 
319 confidence intervals, owing to smaller numbers of participants.  
320
321 The single dose challenge protocol has important potential clinical application. It is very easy to 
322 use and has been positively received by families, as it is much less time consuming than existing 
323 cumulative dose food challenge protocols. Food allergy-related quality of life improved in both 
324 non-reactors and reactors (66). ED05 reactors could potentially be followed up by another single 
325 dose protocol using the ED01 to better delineate their personal thresholds. Clinical services 
326 without the resources for full cumulative dosing food challenges could use this single dose 
327 approach safely, to identify the most dose-sensitive subjects. This could allow advice with regards 
328 to PAL to be personalised. 
329
330 Validation of the log-normal ED05 by these single dose studies, will hopefully motivate the 
331 scientific, food industry and public health communities to adopt this quantitative approach to 
332 decisions to use PAL, starting with the establishment of a defined and widely-accepted reference 
333 dose for peanut in quantitative risk assessment. This would underpin a more evidence-based use 
334 of PAL, by providing sound scientific evidence to protect the vast majority of the peanut allergic 
335 community. 
336
337 How can community reactions help us to understand severity of allergic reactions?
338 Clinical reactions to food mostly occur outside the hospital or clinic setting. It is therefore 
339 important to explore severity in the community to ensure that similar patterns are seen to those 
340 observed in hospital-based studies. Such community studies are challenging, as they are 
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342 patients’ personal perception and experience. The “Allergic Reactions in the Community” 
343 (AllerRIC/AlleRiSC: UK, Ireland) and “Allergic Reactions” (AlleREACT: UK, Ireland, Spain, 
344 Germany, Poland) studies have attempted to address some of these problems by developing and 
345 validating two online reporting tools for food allergic reactions in the community, allowing for 
346 reporting of incidents in near real-time (70,71). The AllerRIC/AlleRiSC study uses a multi-method, 
347 longitudinal design which allows tracking of the same cohort of adult patients over a two-year 
348 period (2014-2016). Adult patients with confirmed food allergies were asked to report their 
349 reactions to food regardless of perceived severity, from mild incidents to anaphylaxis. Participants’ 
350 previous reactions and medical history were recorded in Clinical Record Forms in order to 
351 compare the prospective incidence with the retrospective records. Additionally, a measure of 
352 perceived severity was included in the reporting tool to explore relationships between perception 
353 of severity (from 0 “extremely mild” to 9 “extremely severe) and reported symptoms (70,71). Forty 
354 food-allergic incidents were reported in Ireland and the UK between October 2014 and December 
355 2016. Analyses showed a significant relationship between perceived severity, reported symptoms, 
356 risk perception, and psychological impact (as measured on 5-item scale adapted from Positive 
357 and Negative Affect Scale, PANAS). The related AlleREACT study has gathered real time data 
358 via the internet on reactions in adults with food allergy and parents of affected children from the 
359 UK, Ireland, Spain, Germany, France, and Poland. To date, over 400 reactions have been 
360 reported with a wide variety of severities. Results from these studies will be available in 2019. 
361
362
363 Summary and conclusions
364 Individuals experiencing severe allergic reactions to food make up an important subgroup, they 
365 experience considerable morbidity, and while fatal reactions are rare, they are also unpredictable 
366 (72,73). Within the iFAAM project, a Food Allergy Severity Score (FASS) has been developed 
367 and validated. This has the potential to accurately describe previous allergic reactions at both a 
368 simple and more complex level. Several iFAAM studies are examining the impact of the food 
369 matrix on reaction severity; this would allow us to highlight which foods are particularly high risk 
370 for affected individuals. The presence of co-factors may also impact reaction severity. iFAAM has 
371 investigated the effect of proton-pump inhibitors, which are commonly prescribed, on DBPCFC to 
372 walnut in a two centre study. The potential impact of exercise and sleep deprivation as co-factors 
373 is also being examined in the associated TRACE study. Understanding the magnitude of the 
374 impact of these potential co-factors on thresholds and severity will allow us to better advise 
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376 authorities and the food industry on the level of unintended allergen presence in foods that are 
377 likely to be safe for most individuals with food allergy. These decisions are being driven by 
378 population dose-distribution curves, describing the relationship between dose of allergen and 
379 likelihood of reaction; these are being validated by iFAAM using single dose challenges. This 
380 approach also has the potential to improve patient experience as it is a relatively simple way of 
381 identifying individuals who are likely to react to very small quantities of allergen. Finally iFAAM is 
382 also attempting to understand the experience of individuals who have reactions in the community; 
383 this will allow us to set the experimental studies in the context of real life and to integrate the 
384 impact of biopsychosocial factors, such as physiological and psychological stress, into 
385 subsequent multi-system models.      
386
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